WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Now Available: The U.S. Dredge Report—download today for expert insights, data, and a clear view of the U.S. dredging market.→ Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

79.66 +0.77 (+0.98%)
Streaming Delayed Price Updated: 1:52 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
What's Next: Kymera Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio? ↗
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Why Kymera Therapeutics Stock Crushed it This Week ↗
Via The Motley Fool
News headline image
Demystifying Kymera Therapeutics: Insights From 6 Analyst Reviews ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For Kymera Therapeutics ↗
 
Via Benzinga
News headline image
Preview: Kymera Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Insights Ahead: Kymera Therapeutics's Quarterly Earnings ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 7 Takes On Kymera Therapeutics ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics ↗
 
Via Benzinga
News headline image
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
News headline image
This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Unveiling 6 Analyst Insights On Kymera Therapeutics ↗
 
Via Benzinga
News headline image
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Kymera Therapeutics Stock Is Soaring Today ↗
Kymera's lead pipeline candidate received some good news. 
Via The Motley Fool
News headline image
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics ↗
 
Via Benzinga
News headline image
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details ↗
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
Via Benzinga
News headline image
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
News headline image
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.